Skip to main content
All lobbying filings

AMGEN, INC.

Lobbying for AMGEN INC

 Filing 4th Quarter - Report
4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $3,550,000.00 expenses · posted Jan 20, 2026

Official filing document

 Bills named in this filing 27
  • HR 946
    ORPHAN Cures Act
  • HR 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • HR 1672
    Maintaining Investments in New Innovation Act
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
  • HCONRES 14
    Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
  • HR 1968
    Full-Year Continuing Appropriations and Extensions Act, 2025
  • S 3345
    PBM Price Transparency and Accountability Act
  • HR 6166
    Lowering Drug Costs for American Families Act
  • S 3019
    No Big Blockbuster Bailouts Act
  • HRES 928
    Affirming support for most-favored-Nation drug pricing for United States patients.
  • HR 4317
    PBM Reform Act of 2025
  • HR 5526
    Biosimilar Red Tape Elimination Act
  • HR 2214
    DRUG Act
  • HR 5509
    Safe Step Act
  • HR 5256
    340B ACCESS Act
  • HR 4581
    340B PATIENTS Act of 2025
  • HR 6703
    Lower Health Care Premiums for All Americans Act
  • S 1041
    Affordable Prescriptions for Patients Act
  • S 1040
    Drug Competition Enhancement Act
  • S 2296
    National Defense Authorization Act for Fiscal Year 2026
  • HR 1574
    RESTORE Patent Rights Act of 2025
  • S 1553
    PREVAIL Act
  • HR 3160
    PREVAIL Act
  • S 1546
    Patent Eligibility Restoration Act of 2025
  • HR 3152
    Patent Eligibility Restoration Act of 2025
  • HR 3269
    ETHIC Act
  • HR 6485
    Skinny Labels, Big Savings Act
 Lobbying activity 5
Medicare/Medicaid

Issues related to drug pricing Issues related to Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 S.3345, PBM Price Transparency and Accountability Act H.R. 6166, Lowering Drug Costs for American Families Act S.3019 - No Big Blockbuster Bailouts Act H.Res. 928 - Affirming support for most-favored-Nation drug pricing for United States patients S 3349 PBM Disclosure Act HR 4317 PBM Reform Act

Health Issues

Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act HR 5526 Biosimilar Red Tape Elimination Act HR 2214 DRUG Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 HR 5509 Safe Step act HR 5256 340B Access Act HR 4581 340B Patients Act S2296 NDAA FY2026 National Defense Authorization Act, issued related to Biosecure Act H.R. 6703 Lower Health Care Premiums for All Americans Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act H.Res. 928 Affirming support for most-favored-Nation drug pricing for United States patients S 3349 PBM Disclosure Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act

Taxation/Internal Revenue Code

Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income Public Law 119-21, One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) Issues related to patents and taxes

Copyright/Patent/Trademark

Federal Trade Commission related issues, no specific bill Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS waiver, no specific bill Issues related to patent thickets/product hopping Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling Issues related to patents and taxes S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S.2296-- NDAA (FY 2026 National Defense Authorization Act-- BIOSECURE language) S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) HR 6485 Skinny Labels Big Saving Act

Tariff (miscellaneous tariff bills)

Issues related to tariffs.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem